EA3882-Laboratoire de Biodiversité et Ecologie Microbienne (LUBEM), Universite de Bretagne Occidentale, Brest, France.
UMR1078 'Génétique, Génomique Fonctionnelle et Biotechnologies', INSERM, EFS, Université de Brest, IBSAM, CHU de Brest, University of Brest, Brest, France.
BMJ Open Respir Res. 2019 Mar 12;6(1):e000374. doi: 10.1136/bmjresp-2018-000374. eCollection 2019.
pulmonary infections are the primary cause of morbi-mortality in patients with cystic fibrosis (CF). In this cohort study, the objective was to identify candidate biomarkers of infection within the airway microbiota.
A 3-year prospective multicentre study (PYOMUCO study) was conducted in Western France and included patients initially free for at least 1 year. A 16S-targeted metagenomics approach was applied on iterative sputum samples of a first set of patients (n=33). The composition of airway microbiota was compared according to their status at the end of the follow-up (colonised vs non-colonised), and biomarkers associated with were screened. In a second step, the distribution of a candidate biomarker according to the two groups of patients was verified by qPCR on a second set of patients (n=52) coming from the same cohort and its load quantified throughout the follow-up.
(mainly ) was found to be an enriched phylotype in patients uninfected by (p<0.001). This result was confirmed by quantitative PCR. Conversely, in patients who became positive, significantly decreased before acquisition (p=0.014).
Further studies on replication cohorts are needed to validate this potential predictive biomarker, which may be relevant for the follow-up in the early years of patients with CF. The identification of infection candidate biomarkers may offer new strategies for CF precision medicine.
肺部感染是囊性纤维化(CF)患者发病和死亡的主要原因。在这项队列研究中,目的是确定气道微生物群中感染的候选生物标志物。
在法国西部进行了一项为期 3 年的前瞻性多中心研究(PYOMUCO 研究),纳入了至少 1 年未感染的患者。对一组患者(n=33)的反复痰样本进行了 16S 靶向宏基因组学方法分析。根据随访结束时的 (定植与未定植)状态比较气道微生物群的组成,并筛选与 相关的生物标志物。在第二步中,通过来自同一队列的第二组患者(n=52)的 qPCR 验证候选生物标志物在两组患者中的分布,并在整个随访过程中定量其负荷。
未感染 的患者中, (主要)被发现是一种丰富的菌型(p<0.001)。这一结果通过定量 PCR 得到了证实。相反,在成为阳性的患者中,在 获得之前显著减少(p=0.014)。
需要进一步的复制队列研究来验证这个潜在的预测生物标志物,这可能对 CF 患者早期的随访具有重要意义。感染候选生物标志物的鉴定可能为 CF 精准医学提供新的策略。